Saving changes...

Done

Error

Toceranib Combination Therapy in Canine Cancers

Toceranib Combination Therapy in Canine Cancers

Toceranib Combination Therapy in Canine Cancers

Veterinary Cancer Society
Veterinary Cancer Society
on behalf of Missouri Veterinary Medical Association

$FREE $ FREE $ FREE

$ FREE $ FREE $ FREE
$ 12.50 $ 12.50 $ 12.50
Normal Price: FREE $12.50

Review:

Launch date: 13 Jan 2016

Expiry Date:

Last updated: 29 Aug 2017

Reference: 161830

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

Description

Toceranib Combination Therapy in Canine Cancers Many if not most “targeted” therapies may have their best efficacy when combined with conventional treatments such as chemotherapy, radiation therapy and surgery. However, these types of combinatorial studies often occur relatively late in the development pathway in human oncology. Owing to a relaxed standard of care and a lack of reimbursement issues, these types of combinatorial studies can be performed relatively early in canine cancer. This 30 minute lecture will summarize the studies performed to date utilizing the tyrosine kinase inhibitor toceranib in combination with conventional therapies for canine cancers.

Objectives

Learning Objectives:
• Become familiar with preclinical and human clinical data exploring combination therapy with tyrosine kinase inhibitors and traditional therapy.
• Develop an understanding of clinical data employing combined TKI and chemotherapy/radiation therapy in canine cancer.
Veterinary Cancer Society

Author Information Play Video Bio

Veterinary Cancer Society
on behalf of Missouri Veterinary Medical Association

Dr. Doug Thamm VMD, DACVIM (Oncology); Associate Professor and Barbara Cox Anthony Chair in Oncology
Director of Clinical Research at Colorado State University Flint Animal Cancer Center
Dr. Thamm is also a member of the Developmental Therapeutics Section of the University of Colorado Comprehensive Cancer Center and the Cell and Molecular Biology Graduate Program at Colorado State University. Dr. Thamm received his Bachelors and VMD degrees from the University of Pennsylvania. He completed an Oncology Residency at the University of Wisconsin, and was a researcher there for 5 additional years before joining the faculty at CSU in 2004. He has authored over 100 peer-reviewed publications in veterinary and basic cancer research, and is Co-Editor-In-Chief of the journal Veterinary and Comparative Oncology. His clinical and research interests include novel targeted therapies for animal and human cancer and ways to integrate these therapies with existing treatment."

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Missouri Veterinary Medical Association
  • 0.25 Hours -
    Exam Attempts: 3
    -
    Exam Pass Rate: 50

Faculty and Disclosures

Additional Contributors

Conflicts Declared

Conflicts of Interest declaration by Author:

null

User Reviews (0)

Go Back

Loading...


Saving changes...

Done

Error